anagrelide hydrochloride
SPD422-203
Phase 2 small_molecule completed
Quick answer
anagrelide hydrochloride for Essential Thrombocythaemia is a Phase 2 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Essential Thrombocythaemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed